CA3127786A1 - Gpr35 modulators - Google Patents
Gpr35 modulators Download PDFInfo
- Publication number
- CA3127786A1 CA3127786A1 CA3127786A CA3127786A CA3127786A1 CA 3127786 A1 CA3127786 A1 CA 3127786A1 CA 3127786 A CA3127786 A CA 3127786A CA 3127786 A CA3127786 A CA 3127786A CA 3127786 A1 CA3127786 A1 CA 3127786A1
- Authority
- CA
- Canada
- Prior art keywords
- 6alkyl
- compound
- pharmaceutically acceptable
- solvate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962796459P | 2019-01-24 | 2019-01-24 | |
| US62/796,459 | 2019-01-24 | ||
| US201962873703P | 2019-07-12 | 2019-07-12 | |
| US62/873,703 | 2019-07-12 | ||
| US201962928223P | 2019-10-30 | 2019-10-30 | |
| US62/928,223 | 2019-10-30 | ||
| PCT/US2020/014777 WO2020154492A1 (en) | 2019-01-24 | 2020-01-23 | Gpr35 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3127786A1 true CA3127786A1 (en) | 2020-07-30 |
Family
ID=71733100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3127786A Pending CA3127786A1 (en) | 2019-01-24 | 2020-01-23 | Gpr35 modulators |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11053251B2 (enExample) |
| EP (1) | EP3914256B1 (enExample) |
| JP (1) | JP7588077B2 (enExample) |
| KR (1) | KR102863894B1 (enExample) |
| CN (1) | CN113631168B (enExample) |
| AU (1) | AU2020210930B2 (enExample) |
| BR (1) | BR112021014566A2 (enExample) |
| CA (1) | CA3127786A1 (enExample) |
| IL (1) | IL285074B2 (enExample) |
| MA (1) | MA54825A (enExample) |
| MX (1) | MX2021008941A (enExample) |
| TW (1) | TWI845600B (enExample) |
| WO (1) | WO2020154492A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI845600B (zh) | 2019-01-24 | 2024-06-21 | 美商普羅米修斯生物科學股份有限公司 | Gpr35調節劑 |
| CN114375339A (zh) | 2019-05-14 | 2022-04-19 | 普罗米修斯生物科学公司 | Tl1a患者选择方法、系统和装置 |
| WO2022020617A1 (en) * | 2020-07-23 | 2022-01-27 | Prometheus Biosciences, Inc. | Therapeutic agents targeting gpr35 |
| JP2025513455A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| GB202303387D0 (en) * | 2023-03-08 | 2023-04-19 | Thirtyfivebio Ltd | Compounds |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005119252A2 (en) * | 2004-05-26 | 2005-12-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr35 for the treatment of metabolic-related disorders |
| GB1338235A (en) * | 1970-12-15 | 1973-11-21 | May & Baker Ltd | Azapurinones |
| GB1421970A (en) * | 1973-06-12 | 1976-01-21 | May & Baker Ltd | 8-azapurin-6-one derivatives |
| US4052390A (en) * | 1973-06-12 | 1977-10-04 | May & Baker Limited | Azapurinones |
| GB1561345A (en) | 1976-10-22 | 1980-02-20 | May & Baker Ltd | 8 - azapuring - 6 - ones |
| US4923874A (en) * | 1988-07-21 | 1990-05-08 | G. D. Searle & Co. | Use of 8-azapurin-6-one derivatives for control of hypertension |
| US5474796A (en) | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| FR2845993B1 (fr) | 2002-10-16 | 2005-02-11 | Univ Pasteur | Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques |
| CA2558721A1 (en) * | 2004-02-27 | 2005-09-15 | Pfizer Inc. | Screening method for emulators of neural activity and digestive system using gpr35 |
| US20070287630A1 (en) | 2006-06-12 | 2007-12-13 | Driwater, Inc. | Moisturizing agent with nutrients |
| WO2012167053A1 (en) * | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| TWI707038B (zh) | 2013-08-05 | 2020-10-11 | 美商扭轉生物科技有限公司 | 重新合成之基因庫 |
| US20150273088A1 (en) | 2014-03-28 | 2015-10-01 | Washington University | Zaprinast analogues as glutaminase inhibitors and methods to predict response thereto |
| US10519373B2 (en) | 2014-06-29 | 2019-12-31 | Profile Products, L.L.C. | Bark and wood fiber growing medium |
| US10626180B2 (en) | 2017-04-20 | 2020-04-21 | Cedars-Sinai Medical Center | Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease |
| TW202014217A (zh) * | 2018-04-27 | 2020-04-16 | 美國錫安山醫學中心 | 標靶gpr35以治療發炎性腸病症的組合物及方法 |
| TWI845600B (zh) | 2019-01-24 | 2024-06-21 | 美商普羅米修斯生物科學股份有限公司 | Gpr35調節劑 |
| WO2020163713A1 (en) | 2019-02-08 | 2020-08-13 | Cedars-Sinai Medical Center | Methods, systems, and kits for treating inflammatory disease targeting skap2 |
| MA54903A (fr) | 2019-02-08 | 2021-12-15 | Cedars Sinai Medical Center | Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1 |
| CN114375339A (zh) | 2019-05-14 | 2022-04-19 | 普罗米修斯生物科学公司 | Tl1a患者选择方法、系统和装置 |
| WO2021108694A1 (en) | 2019-11-27 | 2021-06-03 | Cedars-Sinai Medical Center | Predicting extraintestinal manifestations of inflammatory bowel disease |
| WO2022020617A1 (en) | 2020-07-23 | 2022-01-27 | Prometheus Biosciences, Inc. | Therapeutic agents targeting gpr35 |
| JP2023551602A (ja) | 2020-11-13 | 2023-12-08 | プロメテウス バイオサイエンシーズ，インク． | Ｔｌ１ａを標的とする炎症性疾患の治療のための方法、システム、およびキット |
| WO2022140283A1 (en) | 2020-12-21 | 2022-06-30 | Cedars-Sinai Medical Center | Tl1a therapy compositions and methods of treatment therewith |
-
2020
- 2020-01-22 TW TW109102674A patent/TWI845600B/zh active
- 2020-01-23 MX MX2021008941A patent/MX2021008941A/es unknown
- 2020-01-23 CN CN202080024043.7A patent/CN113631168B/zh active Active
- 2020-01-23 MA MA054825A patent/MA54825A/fr unknown
- 2020-01-23 AU AU2020210930A patent/AU2020210930B2/en active Active
- 2020-01-23 BR BR112021014566A patent/BR112021014566A2/pt unknown
- 2020-01-23 IL IL285074A patent/IL285074B2/en unknown
- 2020-01-23 CA CA3127786A patent/CA3127786A1/en active Pending
- 2020-01-23 WO PCT/US2020/014777 patent/WO2020154492A1/en not_active Ceased
- 2020-01-23 KR KR1020217026911A patent/KR102863894B1/ko active Active
- 2020-01-23 EP EP20745502.3A patent/EP3914256B1/en active Active
- 2020-01-23 JP JP2021543122A patent/JP7588077B2/ja active Active
- 2020-01-23 US US16/751,092 patent/US11053251B2/en active Active
-
2021
- 2021-05-18 US US17/323,979 patent/US11773101B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MA54825A (fr) | 2021-12-01 |
| CN113631168A (zh) | 2021-11-09 |
| JP7588077B2 (ja) | 2024-11-21 |
| AU2020210930B2 (en) | 2025-08-14 |
| KR102863894B1 (ko) | 2025-09-23 |
| TW202043234A (zh) | 2020-12-01 |
| EP3914256A4 (en) | 2022-09-28 |
| EP3914256B1 (en) | 2024-05-29 |
| IL285074B1 (en) | 2024-08-01 |
| EP3914256A1 (en) | 2021-12-01 |
| CN113631168B (zh) | 2024-11-19 |
| JP2022518523A (ja) | 2022-03-15 |
| US11053251B2 (en) | 2021-07-06 |
| US11773101B2 (en) | 2023-10-03 |
| AU2020210930A1 (en) | 2021-09-09 |
| IL285074B2 (en) | 2024-12-01 |
| IL285074A (en) | 2021-09-30 |
| US20210380590A1 (en) | 2021-12-09 |
| KR20210119485A (ko) | 2021-10-05 |
| MX2021008941A (es) | 2021-10-13 |
| US20200239476A1 (en) | 2020-07-30 |
| TWI845600B (zh) | 2024-06-21 |
| WO2020154492A1 (en) | 2020-07-30 |
| BR112021014566A2 (pt) | 2022-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018267545B2 (en) | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses | |
| EP3914256B1 (en) | Gpr35 modulators | |
| US20240182490A1 (en) | Bromodomain inhibitors | |
| NL1029726C2 (nl) | Triazolopyridinylsulfanylderivaten als remmers van p38-MAP-kinase. | |
| JP2021509890A (ja) | アミノ酸化合物および使用方法 | |
| CA3158743A1 (en) | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof | |
| EA019723B1 (ru) | ИНГИБИТОРЫ cMET | |
| WO2025117599A1 (en) | Bicyclic heteroaryl compounds as trem2 activators | |
| CA3225785A1 (en) | Cd38 modulators and methods of use thereof | |
| KR20210022646A (ko) | 시아노트리아졸 화합물 및 이의 용도 | |
| US20230151017A1 (en) | Therapeutic agents targeting gpr35 | |
| EP4551560A1 (en) | Haloalkylpyridyl triazole mll1-wdr5 protein-protein interaction inhibitor | |
| AU2021261519A1 (en) | 2-heteroarylaminoquinazolinone derivative | |
| EA048936B1 (ru) | Модуляторы gpr35 | |
| WO2025064325A1 (en) | Gpr35 modulators | |
| WO2025059069A1 (en) | Nlrp3 modulators | |
| HK40059523A (en) | Gpr35 modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240123 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20241114 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20241125 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241125 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241221 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241221 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241221 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250613 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250613 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250613 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250716 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251117 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251117 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251217 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251217 |